Related Experiment Videos
Update on diagnosis and management of essential thrombocythemia
1Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria. heinz.gisslinger@meduniwien.ac.at
Abstract:
Patients with essential thrombocythemia carry a high risk for thromboembolic and bleeding events but they have an almost normal life expectancy. A careful evaluation of the medical history and an exact diagnosis is mandatory to estimate each patient's risk for morbidity and to choose the most appropriate treatment measure. In patients with the need of cytoreductive therapy, the benefits of therapy have to outweigh the potential risks of drug toxicities. Hydroxyurea is the most useful cytoreductive drug for elderly patients; in younger persons, interferon alpha or anagrelide may be the drugs of choice. The combination of anagrelide with acetylsalicylic acid may be contraindicated in patients with a history of bleeding.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Myocarditis IV: Nursing Management
Endocarditis III: Medical Management
Venous Thrombosis IV: Nursing Management
Rheumatic Heart Disease III: Medical Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care